IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects

JAMA Dermatol. 2013 Jun;149(6):742-7. doi: 10.1001/jamadermatol.2013.2625.

Abstract

Importance: In IgG4-related disease (IgG4-RD), skin involvement is rare and associated especially with systemic disease. We report 2 cases of isolated skin IgG4-RD successfully treated with thalidomide and investigated their phenotypic characteristics.

Observations: Two men had cephalic nodules. Skin biopsies revealed dense lymphocytic infiltrates with numerous plasma cells and fibrosis. IgG4-RD was confirmed by very high IgG4+ to IgG+ plasma cells ratios of 76% (patient 1) and 100% (patient 2). The serum IgG4 level was normal. There was no other organ involvement. Thalidomide therapy was introduced. After 6 months, lesions were in remission. Patient 1 required long-term, low-dose thalidomide, whereas patient 2 stopped treatment and showed no relapse. Immunostaining revealed numerous FoxP3+ cells in the interfollicular areas, which decreased with treatment in patient 2, and numerous follicular helper T lymphocytes (TFH) within the follicular germinal centers. There were numerous mast cells; some stained for interleukin (IL)-6, and expression of phospho-Smad2/3 was demonstrated.

Conclusions and relevance: IgG4-RD may be skin limited. Cutaneous infiltrates comprise numerous FoxP3+ cells that may interact with mast cells to produce IL-6 and stimulate fibrosis synthesis via the transforming growth factor β/phospho-Smad2/3 pathway. The role of TFH cells remains to be studied. IgG4-RD should be added to the causes of cutaneous pseudolymphomas. Thalidomide could be considered as a therapeutic option in IgG4-RD.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Forkhead Transcription Factors / metabolism
  • Humans
  • Immunoglobulin G / immunology*
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Remission Induction / methods
  • Secondary Prevention
  • Skin Diseases / drug therapy*
  • Skin Diseases / immunology
  • Skin Diseases / pathology
  • T-Lymphocytes, Helper-Inducer / immunology
  • Thalidomide / therapeutic use*
  • Treatment Outcome

Substances

  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Thalidomide